Syndax Announces Participation in September Investor Conferences
SNDXNEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDXNEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax's Revumenib Shows 67% CR, 88% ORR, And 100% MRD Negativity Among Responders In Combo With Venetoclax/Azacitidine For Older, Newly Diagnosed mNPM1 And KMT2Ar AML Patients; Phase 3 EVOLVE-2 Trial Now Enrolling; Published In The 'Journal Of Clinical
SNDXSyndax Presents New Revuforj (revumenib) Data In Relapsed/Refractory mNPM1 And NUP98r Acute Leukemia From AUGMENT-101 Trial At EHA 2025
SNDXSyndax Pharma: Multiple Abstracts Showcasing Clinical Data For Revuforj Accepted For Presentation At EHA Annual Congress Meeting
SNDXSyndax Presents Data Showcasing Revuforj And Niktimvo At EHA 2025
SNDXSyndax Pharma Publishes Data From Pivotal Phase 2 Portion Of AUGMENT-101 Trial Of Revumenib In Patients With R/R mNPM1 Acute Myeloid Leukemia In Blood
SNDXScotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Raises Price Target to $17
SNDXGuggenheim Reiterates Buy on Syndax Pharmaceuticals, Maintains $32 Price Target
SNDXSyndax Pharmaceuticals Q1 EPS $(0.98) Beats $(1.03) Estimate, Sales $20.04M Beat $14.43M Estimate
SNDXSyndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
SNDXJP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $41
SNDXJP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $39
SNDXCitigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $42
SNDXHC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target
SNDXSyndax Sees Research & Development Expenses Of $65M-$70M In Q1, $260M-$280M In 2025
SNDXSyndax Pharmaceuticals Q4 2024 GAAP EPS $(1.10) Misses $(1.01) Estimate, Sales $7.68M Miss $85.91M Estimate
SNDXCitigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $45
SNDXHC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51
SNDXSyndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation
SNDXHC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $47
SNDXSyndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.
SNDXSyndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate
SNDXSyndax Announces New Data From Secondary Analysis Of The Pivotal AGAVE-201 Trial Of Niktimvo In Chronic Graft-Versus-Host Disease To Be Presented At 66th ASH Annual Meeting
SNDXSyndax Pharmaceuticals's Earnings: A Preview
SNDXWatching Syndax Pharmaceuticals; Traders Circulate Ray Blanco Mentions Stock As A Pick On Investors Newsletter
SNDXJP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
SNDX